Obesity engine with pricing and focus risk
- Mounjaro and Zepbound drove 48 percent total revenue growth in Q2 2026, creating huge gains and heavy concentration.
- Management raised full year revenue guidance by $2.5 billion, now expecting $85 billion to $87 billion in 2026.
- Underlying U.S. prices fell 9 percent in Q2 2026, showing the trade off between volume expansion and price compression.
- The Medicare GLP 1 Bridge program launched on July 1, 2026, expanding the addressable U.S. obesity market.
- Retatrutide posted strong Phase 3 weight loss data, securing Lilly's lead in the next generation of injectables.
- Key risks are manufacturing execution, payer pricing pressure, and the heavy bet on one treatment class.
A weight loss leader with one main engine
Lilly is one of the main global suppliers of incretin medicines, a drug class used for type 2 diabetes and obesity. Mounjaro and Zepbound are the core products, combining for $14.9 billion of revenue in Q2 2026 and driving a 48 percent jump in total company sales. International demand is also growing fast, with European revenue up 55 percent. That is why Finn's growth and performance view remains strong.
The bull case improved after Q2 2026. Management raised full year revenue guidance by $2.5 billion at the midpoint, now expecting $85 billion to $87 billion. The Medicare GLP 1 Bridge program launched on July 1, rapidly increasing prescriptions for Zepbound and Foundayo. Retatrutide, a triple agonist drug in the pipeline, posted Phase 3 weight loss data that approaches bariatric surgery levels, securing Lilly's lead in the next generation of injectables.
The bear case centers on pricing pressure and execution risk. The massive volume growth comes at a cost, as underlying U.S. pricing for these drugs declined 9 percent in Q2 2026. The next year will come down to whether prescription growth from the Medicare Bridge program can outpace these price cuts, whether the global manufacturing scale up can happen without problems, and how the FDA views the retatrutide submission targeted for early 2027.
Patents, scale, and access deals
Lilly discovers, tests, makes, and sells branded prescription drugs. It spends heavily on research and development, then runs clinical trials to prove a drug works and is safe. If regulators approve the drug, patents give Lilly a period with limited generic competition. That is when the company can earn back the cost of research and make a profit.
Most revenue comes through sales to wholesalers, pharmacies, and healthcare providers around the world. The model now depends most on cardiometabolic drugs. Mounjaro treats type 2 diabetes. Zepbound treats obesity. Next generation drugs like oral Koundeo and injectable retatrutide are meant to expand the franchise. These drugs are driving massive volume growth, while lower realized prices are partly offsetting that growth.
Lilly also has other products that matter. Verzenio in cancer, Taltz in immunology, Jardiance in diabetes, Trulicity in diabetes, and Kisunla in Alzheimer's disease help broaden the business. LillyDirect adds a direct to consumer path by connecting patients with telehealth providers and home delivery for some medicines. Lilly Employer Connect is a newer platform for employers to offer obesity medicines.
The model can break in a few clear ways. Lilly must keep building enough manufacturing capacity for incretins without quality problems or delays. It must also accept lower prices in some channels to reach more patients. The core question is whether selling to many more patients at lower prices creates more profit than selling to fewer patients at higher prices.
The drugs that matter most
Mounjaro (tirzepatide, type 2 diabetes)
Mounjaro is Lilly's leading diabetes incretin and a main driver of recent revenue growth. Together with Zepbound, it combined for $14.9 billion of sales in Q2 2026.
Zepbound (tirzepatide, obesity)
Zepbound is the obesity brand of tirzepatide. It is a major growth driver, but access can change fast because large payers can demand lower prices.
Foundayo / Koundeo (orforglipron, oral GLP 1)
Foundayo is Lilly's oral GLP 1 obesity drug. Early launch data showed most prescriptions were new to the class, supporting the market expansion case.
Retatrutide (triple agonist, obesity)
Retatrutide is an experimental injectable obesity drug that posted Phase 3 weight loss data approaching bariatric surgery levels. A U.S. filing is planned for early 2027.
Trulicity (dulaglutide, diabetes)
Trulicity is an older injectable GLP 1 for type 2 diabetes. It faces pricing pressure and volume declines as newer incretins take the lead.
Verzenio (abemaciclib, oncology)
Verzenio is a cancer drug used mainly in breast cancer. It helps diversify Lilly away from obesity and diabetes.
Taltz (ixekizumab, immunology)
Taltz treats immune conditions such as psoriasis and psoriatic arthritis. It provides recurring revenue and adds balance to the portfolio.
Kisunla (donanemab, Alzheimer's disease)
Kisunla is approved for early symptomatic Alzheimer's disease. It gives Lilly a non obesity growth path, but adoption and reimbursement are still early.
One segment, one big concentration
Lilly reports one segment: human pharmaceutical products. The structured mix below separates the named Mounjaro and Zepbound concentration from the rest of the business, reflecting their dominance of total revenue.
What could break the Lilly thesis
Too much reliance on incretins
High impact · Medium oddsMounjaro and Zepbound continue to drive the vast majority of growth, combining for $14.9 billion in Q2 2026 revenue. A safety issue, stronger competitor, or shift in doctor use for incretin drugs would hit most of Lilly's growth at once. Next generation drugs like retatrutide keep Lilly tied to the same broad class.
Payers take more price
High impact · High oddsLilly has agreements with the U.S. government to lower Medicaid and some other drug prices. The pressure is already showing, with underlying U.S. prices falling 9 percent in Q2 2026. The company must sell significantly more volume through new channels like the Medicare GLP 1 Bridge program to offset these cuts.
Manufacturing falls behind demand
High impact · Medium oddsLilly is carrying out large manufacturing expansion plans globally, including new sites in Indiana and Ireland, to meet demand for obesity and diabetes drugs. Any delay, quality issue, or capacity shortfall could lead to shortages, lost sales, or regulatory problems tied to manufacturing standards.
Competition and counterfeit incretins
Medium impact · Medium oddsDiabetes, obesity, and oncology are competitive markets. Rivals are developing injectable and oral obesity drugs that could lower Lilly's share or force lower prices. Lilly also warns about counterfeit, misbranded, adulterated, and compounded incretins, which can confuse patients and harm trust in the category.
Patent or regulatory setbacks
Medium impact · Medium oddsLilly's profit depends on patents and regulatory approvals. If patent protection weakens, generic or biosimilar competition could arrive sooner than expected. Regulatory setbacks can also delay new uses for existing drugs, which happened previously when the FDA asked for more data on tirzepatide in heart failure.
In one breath
How does Eli Lilly make most of its money today?
Lilly makes most of its revenue from patented prescription drugs. Today the biggest drivers are Mounjaro and Zepbound, which treat type 2 diabetes and obesity and combined for $14.9 billion in Q2 2026 sales.
What is Koundeo and why does it matter?
Koundeo, also called orforglipron or Foundayo, is Lilly's oral GLP 1 drug for obesity. It matters because it is easier to take than an injection and early data showed it is bringing new patients into the obesity market.
Why is pricing such a big issue for Lilly?
Lilly is gaining access to larger patient groups through government programs, but often at lower prices. In Q2 2026, underlying U.S. prices for its drugs fell 9 percent, meaning volume must grow fast enough to make up the difference.
Is Eli Lilly's stock price already assuming success?
Finn's valuation view is low, while growth and performance score much higher. That means the business is strong, but the market already expects huge profits from obesity drugs, Medicare access, and future pipeline wins.
